Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma
Author:
Affiliation:
1. Melanoma Unit, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14728214.2021.1901884
Reference94 articles.
1. Global Cancer Observatory https://gco.iarc.fr/
2. Mechanisms of resistance to immune checkpoint inhibitors
3. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation
5. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effects of PD-L1 Inhibitors on Mitochondrial Function in Melanoma A375 Cells: Unveiling a Shielded Drug Resistance Mechanism;2024-08-09
2. The prognostic value of VISTA combined with imaging in pancreatic cancer patients;2024-01-15
3. Quercetin Limits Tumor Immune Escape through PDK1/CD47 Axis in Melanoma;The American Journal of Chinese Medicine;2024-01
4. Exploring the potential of dual-sensitive hydrogels for personalized precision medicine applications;Journal of the Taiwan Institute of Chemical Engineers;2023-12
5. Upgrading Melanoma Treatment: Promising Immunotherapies Combinations in the Preclinical Mouse Model;Current Cancer Therapy Reviews;2023-10-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3